| 000 | 02429 a2200649 4500 | ||
|---|---|---|---|
| 005 | 20250513230051.0 | ||
| 264 | 0 | _c20010419 | |
| 008 | 200104s 0 0 eng d | ||
| 022 | _a0889-8588 | ||
| 024 | 7 |
_a10.1016/s0889-8588(05)70192-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGarcia-Manero, G | |
| 245 | 0 | 0 |
_aThe hyper-CVAD regimen in adult acute lymphocytic leukemia. _h[electronic resource] |
| 260 |
_bHematology/oncology clinics of North America _cDec 2000 |
||
| 300 |
_a1381-96, x-xi p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Review | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnti-Infective Agents _xadministration & dosage |
| 650 | 0 | 4 | _aAntibiotic Prophylaxis |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 | _aBiomarkers, Tumor |
| 650 | 0 | 4 |
_aCentral Nervous System Neoplasms _xprevention & control |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aDexamethasone _xadministration & dosage |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunization, Passive |
| 650 | 0 | 4 | _aImmunophenotyping |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aInjections, Spinal |
| 650 | 0 | 4 | _aKaryotyping |
| 650 | 0 | 4 |
_aMercaptopurine _xadministration & dosage |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPhiladelphia Chromosome |
| 650 | 0 | 4 |
_aPrecursor Cell Lymphoblastic Leukemia-Lymphoma _xdrug therapy |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTexas _xepidemiology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVincristine _xadministration & dosage |
| 700 | 1 | _aKantarjian, H M | |
| 773 | 0 |
_tHematology/oncology clinics of North America _gvol. 14 _gno. 6 _gp. 1381-96, x-xi |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0889-8588(05)70192-1 _zAvailable from publisher's website |
| 999 |
_c11087154 _d11087154 |
||